Dilution Sequence Protocol

Similar documents
Dilution Sequence Protocol

Dilution Sequence Protocol

Mixing Methacholine Dilutions for Bronchoprovocation Challenge Testing

TEV-TROPIN [somatropin (rdna origin) for injection] 5 mg & 10 mg

3. This solution retains potency for 2 8 hours at room temperature after reconstitution.

CHAPTER 10 Reconstitution of Powdered Drugs

PREPARATION AND SELF-ADMINISTRATION INSTRUCTIONS FOR PATIENTS

RECONSTITUTION AND ADMINISTRATION INSTRUCTIONS FOR HEALTHCARE PROFESSIONALS

RECONSTITUTION AND ADMINISTRATION INSTRUCTIONS FOR HEALTHCARE PROFESSIONALS. Hereditary Angioedema

Aseptic Techniques. Techniques for Sterile Compounding. Pharmacy Technician Training Systems Passassured, LLC

PREPARATION AND SELF-ADMINISTRATION INSTRUCTIONS FOR PATIENTS

helping patients thrive Clotting Factor Concentrate Information

RECOMBINATE. [Antihemophilic Factor (Recombinant)] (For intravenous use only)

Note: Does have indication for Prophy- suggest 25 units/kg every other day

See Important Reminder at the end of this policy for important regulatory and legal information.

Safety Data Sheet MasterSet DELVO ESC also DELVO ESC Revision date : 2014/12/16 Page: 1/6

Independent Health Facilities

Health Products Regulatory Authority

TECHNICAL BULLETIN. TriControls. Control Materials for Liquid QC and Calibration Verification

Varithena Delivery System Instructions for Use

PERFORMANCE OF A FINGERSTICK

Patients Guide for Self Administering Intravenous Antibiotics General points

Varithena Delivery System Instructions for Use INSTRUCTIONS FOR USE Please read the Product Monograph before using the product.

extraction of EG and DEG from the matrix. However, the addition of all diluent at once resulted in poor recoveries.

APPENDIX 5. Donor Heart Perfusion & Preservation Protocol for NORS Teams in the UK

Quantos Automated Dosing Solution Preparation Precise concentrations Process compliance Minimize out-of-specs

CSL Behring PACKAGE LEAFLET: INFORMATION FOR THE USER

Aseptic processing. the starting material to the finished product, should be controlled by Validation Control of the aseptic process

Monosed ESR Non-Vacuum Tube USER S MANUAL

McGill University Health Center Pediatric Drug Infusion Preparation Chart

MSD 96-Well MULTI-ARRAY CRP Assay

Making Life Easier Easypump II

Reconstitution and Administration Instructions for Healthcare Professionals.

IVIG Educational Presentation

HUMAN IL6 KITS PROTOCOL

INSTRUCTIONS FOR USE (US)

INSTRUCTIONS FOR USE - US RaplixaSpray (Raplixa Delivery Device)

CGMP KITS PROTOCOL ASSAY PRINCIPLE

COMPOUNDING WITH HAZARDOUS DRUGS

STANDARD OPERATING PROCEDURE ADVANCED INTRAVENOUS TRAINING ARM (S )

MATERIAL SAFETY DATA SHEET. Known Hazardous Components CAS Number Percent. Stop Solution 99% Known Hazardous Components CAS Number Percent

96-well Serum/Plasma Fatty Acid Kit Non-Esterified Fatty Acids Detection 100 point kit Cat# SFA-1

C O L O G Y. New. g u O N. l o t a C a. The high security connection

B. A clinical emergency exists in which a profound hypoxia is determined to be present.

Stimate Nasal Spray SDS Revision Date: 10/22/2015

MATERIAL SAFETY DATA SHEET

USP <797> LABELING ESTABLISHING BEYOND-USE DATES AND IN-USE TIMES

Clinician Guide. Baxter Elastomeric Devices. Promoting patient-centric care

MATERIAL SAFETY DATA SHEET

SAFETY DATA SHEET Oxycodone and Acetaminophen Tablets, USP

Multiplate Platelet Function Analyzer: An Overview

Before you use KINERET. When you must not use it. Do not use KINERET if you have. using a medicine known as tumour necrosis factor (TNF) antagonist.

ab IgG1 Human ELISA Kit

MSD 96-Well MULTI-ARRAY Human (6E10) Abeta 42 Ultra-Sensitive Kit

Before you use. When you must not use it

MSD 96-Well MULTI-ARRAY Human (6E10) Abeta 40 Ultra-Sensitive Kit

RayBio Human vwf ELISA Kit

Specimen Collection. Lead Screen Filter Paper Testing Dried Blood Spots (DBS) Laboratory Services February 2017

96-well Serum/Plasma Fatty Acid Kit Non-Esterified Fatty Acids Detection 500 Point Kit Cat# SFA-5

PRODUCT SAFETY DATA SHEET Carprieve Injection

DRUG STABILITY AN EVIDENCE REVIEW AND DEVELOPMENT OF A NATIONAL METHODOLOGY FOR STABILITY TESTING OF AGENTS AND DEVICES

PUMP WITH FIXED FLOW RATE. Instructions for Use

TITLE: Pulse Oximetry COMPETENCY #: Resp #1 NEW COMPETENCY REVISION DATE: 10/18/12 EMPLOYEE NAME. DATE INITIAL RE-EVALUATION ANNUAL (if required) PRN

PACKAGE LEAFLET: INFORMATION FOR THE USER. Exembol Multidose 100 mg/ml concentrate for solution for infusion. Argatroban Monohydrate

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

GAZYVA(R) Vials (1,000 mg/40 ml)

Oxygen Dialflow Meter. Instructions for Use

US - OSHA SAFETY DATA SHEET

Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent

MSD 96-Well MULTI-ARRAY and MULTI-SPOT Human Granulocyte Colony Stimulating Factor (hg-csf) Ultrasensitive Assay

Kcentra SDS Revision Date: 06/03/2015

Big Wipes 4x4 Health & Safety Data Sheet

Ceftriaxone for Injection, USP 500mg Vial: 1g Vial: 2g Vial: 10g Vial:

Chemical Analysis for Methyltestosterone

WHY IS PREVENTION IMPORTANT?

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

In case of medical emergencies, please contact your local poison control center.

Section 1: Identification. Section 2: Hazard(s) Identification

Corning Step-R. Repeating Pipettor. Instruction Manual

MATERIAL SAFETY DATA SHEET SECTION 1. IDENTIFICATION OF SUBSTANCE AND CONTACT INFORMATION NOBIVAC LEPTO4

3M MATERIAL SAFETY DATA SHEET 3M(TM) Attest(TM) Biological Indicators 1262 (steam), 1262P, 1261 (flash), 1261P 11/05/2004

Certificate of Compliance Section 1 - PRODUCT AND COMPANY IDENTIFICATION

300 Northfield Road Bedford, OH Telephone: (440) or- (800) MATERIAL SAFETY DATA SHEET. Section I - IDENTITY

Propylene Glycol. Safety Data Sheet. 1. Product Identity. Product Number: Hazardous Ingredients

Assisting with Insertion. Care of Intraspinal Catheters

1.) Take an alcohol swab to the stopper of both your peptide vial and the vial of the dilutent.

Voncento SDS Revision Date: 06/04/2015

PRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate)

Ocular Irritation: Dilution Method

Contacts. Quick Start Guide

BATCH MANUFACTURING RECORD FOR PRODUCT X,

MATERIAL SAFETY DATA SHEET

LABELLING OF MEDICAL GAS CONTAINERS

CTG Certification Protocol -- Version 3.0 SUMMARY

Understanding Tracheostomy Care for your Child

CICRA EMERGENCY PROCEDURES

Safety Data Sheet. Section 1: Identification. Material Name: CHILDREN S ACETAMINOPHEN ORAL SUSPENSION

PRESSURISED PAINT CONTAINER

MATERIAL SAFETY DATA SHEET

Material Safety Data Sheet PROFORCE NO RINSE FLOOR CLEANER

Transcription:

Dilution Sequence Protocol ATS Short Quadrupling Doses 0.0625 0.25 1 4 16 Provocholine 1600 mg/vial (US NDC 64281-016-01) 1 Provocholine (methacholine chloride USP) powder for solution, for inhalation, is marketed in the United States, Canada and other countries. Provocholine is indicated for the diagnosis of bronchial airway hyperreactivity in subjects who do not have clinically apparent asthma. Provocholine is a bronchoconstrictor agent for diagnostic purposes only and should not be used as a therapeutic agent. Provocholine inhalation challenge should be performed only under the supervision of a physician trained in and thoroughly familiar with all aspects of the technique of methacholine challenge, all contraindications, warnings and precautions, and the management of respiratory distress. Emergency equipment and medication should be immediately available to treat acute respiratory distress. For complete prescribing information, please consult the Package Insert which is available for download at www.provocholine.com or on request by calling Methapharm Medical Information at 1-800-287-7686 519-751-3602 ext. 7804 or faxing us at 519-751-9149. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA(332)-1088. Provocholine is a registered trademark of Methapharm Inc. Copyright Methapharm Inc. 2017. This information is provided as a professional courtesy, and it is intended to provide data available to us that may assist you in deriving your own conclusions and opinions. This information is not intended to advocate any indications, dosage, or other claim that is not described in the package insert. www.provocholine.com

Introduction Dilution Sequence Protocol This dilution sequence was prepared according to the Guidelines for Methacholine and Exercise Challenge Testing, published in 2000 by the American Thoracic Society. This protocol is commonly known as the ATS Short, and is available for download at http://www.thoracic.org/statements/resources/pfet/methacholine1-21.pdf. The following are step-by-step instructions on how to reconstitute a 1600 mg vial of Provocholine into the five (5) requisite concentrations for use in a Provocholine challenge to test 16 to 40 patients. Please refer to the Provocholine package insert for full instructions and safety precautions. Precise sterile mixing is essential for the accuracy of the test results and to maintain patient safety. Only trained individuals should mix and label Provocholine solutions. 2

Introduction Important Notes Do not inhale powder during preparation of dilutions. Do not handle Provocholine if you have asthma or hay fever. Provocholine dilutions should be mixed by a pharmacist or other well-trained individual using sterile technique. All vials should be labeled, filling in the appropriate lot number, concentration, diluent, preparation date, initials of person preparing, and expiration date. To reduce back pressure, vent vials with an extra needle as needed. All dilutions should be mixed in sterile USP Type I borosilicate glass vials. All dilutions should use one of the approved diluent options listed in your Provocholine package insert and use the same diluent throughout. 3

Overview Supplies Required Supplies required for the dilution of a single (1) vial of Provocholine 1600 mg Quantity Description 1 1600 mg vial of Provocholine 3 100 ml diluent* 5 50 ml sterile empty USP Type I borosilicate glass vials* 2 50 ml syringes* 2 20 Gauge, 1" syringe needles* 9 Alcohol preparation pads or swabs* 1 Set of directions 1 Provocholine Dilution Sequence Check Sheet and Control Record 1 Package Insert for Provocholine * These supplies may require alternate quantities depending on your protocol. 4

Overview Dilution Process TAKE Provocholine ADD Diluent (Shake well) Provocholine 1600 mg 40 ml 40 mg/ml 20 ml from Stock Solution 30 16 mg/ml 12.5 ml from Vial A 37.5 ml 4 mg/ml 12.5 ml from Vial B 37.5 ml 1 mg/ml OBTAIN DILUTION 12.5 ml from Vial C 37.5 ml 0.25 mg/ml 12.5 ml from Vial D 37.5 ml 0.0625 mg/ml VIAL NAME Stock Solution* 40 mg/ml Vial A 16 mg/ml Vial B 4 mg/ml Vial C 1 mg/ml Vial D 0.25 mg/ml Vial E 0.0625 mg/ml *DO NOT ADMINISTER STOCK SOLUTION TO PATIENTS. 5

Overview Labeling Fill in ALL information on labels. Include 14 day expiration date on vials A E. Type of Diluent Used Dilution Strength Preparation Date Lot Number Expiry Date Initials of Person Performing Dilution 6

Dilution Process Getting Started 1. Attach labels to sterile empty vials. 2. Wipe down the stoppers of the Provocholine vial, diluent vials, and sterile empty vials with alcohol prep pads. 3. Label two (2) appropriately sized syringes (one for Provocholine, one for diluent), and attach needles to each. 7

Dilution Process Step 1: Preparing the Stock Solution Provocholine 40 mg/ml Stock Solution 1. Using the diluent needle and syringe: draw 40 ml of diluent. transfer the 40 ml of diluent to the Provocholine 1600 mg vial, creating the Provocholine 40 mg/ml stock solution. 2. Shake well. NOTE: DO NOT ADMINISTER STOCK SOLUTION TO PATIENTS. 8

Dilution Process Step 2: Preparing Vial A Provocholine 16 mg/ml Solution 1. Using the Provocholine draw 20 ml from stock solution. transfer the 20 ml to Vial A. 1. Using the diluent add 30 ml of diluent to Vial A. 2. Shake well. After completing Step 2 Stock solution vial contains 20 ml of Provocholine solution at 40 mg/ml. - AND - Vial A contains 50 ml of Provocholine solution at 16 mg/ml. VIAL A 16 mg/ml VIAL A 16 mg/ml 9

Dilution Process Step 3: Preparing Vial B Provocholine 4 mg/ml Solution VIAL A 16 mg/ml 1. Using the Provocholine draw 12.5 ml from Vial A. 1. Using the diluent add 37.5 ml of diluent to Vial B. After completing Step 3 Vial A contains 37.5 ml of Provocholine solution at 16 mg/ml. transfer the 12.5 ml to Vial B. 2. Shake well. - AND - Vial B contains 50 ml of Provocholine solution at 4 mg/ml. VIAL B 4 mg/ml VIAL B 4 mg/ml 10

Dilution Process Step 4: Preparing Vial C Provocholine 1 mg/ml Solution VIAL B 4 mg/ml 1. Using the Provocholine draw 12.5 ml from Vial B. 1. Using the diluent add 37.5 ml of diluent to Vial C. After completing Step 4 Vial B contains 37.5 ml of Provocholine solution at 4 mg/ml. transfer the 12.5 ml to Vial C. 2. Shake well. - AND - Vial C contains 50 ml of Provocholine solution at 1 mg/ml. VIAL C 1 mg/ml VIAL C 1 mg/ml 11

Dilution Process Step 5: Preparing Vial D Provocholine 0.25 mg/ml Solution VIAL C 1 mg/ml 1. Using the Provocholine draw 12.5 ml from Vial C. 1. Using the diluent add 37.5 ml of diluent to Vial D. After completing Step 5 Vial C contains 37.5 ml of Provocholine solution at 1 mg/ml. transfer the 12.5 ml to Vial D. 2. Shake well. - AND - Vial D contains 50 ml of Provocholine solution at 0.25 mg/ml. VIAL D 0.25 mg/ml VIAL D 0.25 mg/ml 12

Dilution Process Step 6: Preparing Vial E Provocholine 0.0625 mg/ml Solution After completing Step 6 VIAL D 0.25 mg/ml 1. Using the Provocholine draw 12.5 ml from Vial D. transfer the 12.5 ml to Vial E. 1. Using the diluent add 37.5 ml of diluent to Vial E. 2. Shake well. Vial D contains 37.5 ml of Provocholine solution at 0.25 mg/ml. - AND - Vial E contains 50 ml of Provocholine solution at 0.0625 mg/ml. NOTE: VIAL E 0.0625 mg/ml VIAL E 0.0625 mg/ml Transfer all dilutions (in vials A through E) to nebulizer through the 0.22 μm sterile bacterial retentive filter (Millex GV ).* *Do not attach filter until AFTER solution has been drawn into syringe 13

Conclusion Storage Instructions Provocholine powder should be stored at 59º to 86ºF (15º to 30ºC). Dilutions A through E (16 mg/ml through 0.0625 mg/ml) should be stored at 36º to 46ºF (2º to 8ºC) in a refrigerator for no more than 2 weeks. Freezing does not affect the stability of dilutions A through E (16 mg/ml through 0.0625 mg/ml). 14

Conclusion Summary of Procedure 1. Attach two (2) needles to two (2) 50 ml syringes and label one (1) for Provocholine and one (1) for diluent. 2. Remove plastic covers from Provocholine and diluent vials; line up all sterile empty vials. 3. Fill in information and attach labels to the Provocholine and the sterile empty vials. 4. Wipe down the stoppers of the Provocholine vial, diluent vials, and sterile empty vials with alcohol prep pads. 5. Using the diluent syringe, add 40 ml of diluent into the Provocholine 1600 mg vial, creating the Provocholine 40 mg/ml Stock Solution. 6. Using the Provocholine syringe, draw 20 ml from stock solution and transfer to Vial A. Using the diluent syringe, draw 30 ml of diluent and transfer to Vial A. Shake well. This becomes VIAL A 16 mg/ml. 7. Using the Provocholine syringe, draw 12.5 ml from Vial A and transfer to Vial B. Using the diluent syringe, draw 37.5 ml of diluent and transfer to Vial B. Shake well. This becomes VIAL B 4 mg/ml. 15

Conclusion Summary of Procedure 8. Using the Provocholine syringe, draw 12.5 ml from Vial B and transfer to Vial C. Using the diluent syringe, draw 37.5 ml of diluent and transfer to Vial C. Shake well. This becomes VIAL C 1 mg/ml. 9. Using the Provocholine syringe, draw 12.5 ml from Vial C and transfer to Vial D. Using the diluent syringe, draw 37.5 ml of diluent and transfer to Vial D. Shake well. This becomes VIAL D 0.25 mg/ml. 10. Using the Provocholine syringe, draw 12.5 ml from Vial D and transfer to Vial E. Using the diluent syringe, draw 37.5 ml of diluent and transfer to Vial E. Shake well. This becomes VIAL E 0.0625 mg/ml. 16

Conclusion Summary of Procedure NOTE To reduce back pressure, vent vials with an extra needle as needed. Transfer all dilutions (in vials A through E) to nebulizer through the 0.22 μm sterile bacterial retentive filter (Millex GV ).* *Do not attach filter until AFTER solution has been drawn into syringe. 17

Conclusion Dilution Check Sheet and Control Record PROVOCHOLINE DILUTIONS FOR CHALLENGE TESTING Date: Prepared by: Checked by: Provocholine (see label on vial) Lot Number: Expiration Date: Diluent Lot Number: Expiration Date: TAKE Provocholine ADD Diluent (Shake well) OBTAIN DILUTION VIAL NAME INITIAL Provocholine 1600 mg 40 ml 40 mg/ml Stock Solution* 40 mg/ml 20 ml from stock solution 30 ml 16 mg/ml Vial A 16 mg/ml 12.5 ml from Vial A 37.5 ml 4 mg/ml Vial B 4 mg/ml 12.5 ml from Vial B 37.5 ml 1 mg/ml Vial C 1 mg/ml 12.5 ml from Vial C 37.5 ml 0.25 mg/ml Vial D 0.25 mg/ml 12.5 ml from Vial D 37.5 ml 0.0625 mg/ml Vial E 0.0625 mg/ml *DO NOT ADMINISTER STOCK SOLUTION TO PATIENTS. 18